The IPC Rapid Communications initiative aims to deliver concise, expert perspectives on emerging developments in psoriasis research, clinical practice, and health policy. Each publication highlights urgent or important issues where swift dissemination of expert insights can inform and improve patient care worldwide.
New discoveries, therapies, and data in psoriasis care evolve quickly—and clinicians need access to expert interpretation as soon as possible.
Rapid Communications allow IPC experts to respond to new evidence or pressing issues in real time, bridging the gap between guideline updates and helping practitioners stay current with global best practices.
Each Rapid Communication is a short, focused publication, typically under 500 words with up to five references, developed by IPC experts. Up to four are released annually and may take the form of expert commentaries, white papers, or position statements.
Selected manuscripts are fast-tracked for publication in peer-reviewed journals or shared on the IPC website to ensure timely global access.
Ideas are solicited annually from IPC members, Corporate Partners, and patient partner organizations. Submissions are evaluated by the IPC Editorial Committee based on:
Authors are chosen from among those who proposed the idea with attention to expertise and geographic diversity. While IPC aims to include idea contributors whenever possible, participation as an author is not guaranteed. Each manuscript undergoes a structured review and approval by the IPC Board of Directors before publication.
Stay up to date with the newest expert commentaries shaping psoriasis care.
Management of Moderate-to-Severe Psoriasis in Patients with Cancer: Guidance from the International Psoriasis Council. Gisondi P, Carrascosa JM, Jo SJ, et al. JAAD Reviews. Published online August 14, 2026. doi.org/10.1016/j.jdrv.2026.08.004.
Bridging Psoriasis and Metabolic Comorbidities: Toward Comprehensive Patient Management. Priorities from the International Psoriasis Council. Strober BE, Treichel AM, Bowcock AM, et al. J Am Acad Dermatol. Published online July 25, 2026. doi:10.1016/j.jaad.2026.07.066
International Psoriasis Council Psoriasis Disease Severity Reclassification: Update on Validity, Acceptance, and Implementation. Strober BE, Blauvelt A, van de Kerkhof PC, et al. J Am Acad Dermatol. 2025 Oct;93(4):1154-1157. doi: 10.1016/j.jaad.2025.05.1445. Epub 2025 Jun 6. PMID: 40484137.
These key clinical topics are under active development for upcoming Rapid Communication publications.
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.
